Novo Nordisk Commits Up to $2.1 Billion to MIT Spinoff Vivtex for Oral Peptide Delivery
Novo Nordisk signed a deal worth up to $2.1 billion with Vivtex Corporation, an MIT spinoff co-founded by Bob Langer, to develop next-generation oral biologic medicines for obesity and diabetes. Vivtex's AI-driven platform screens thousands of drug delivery formulations per day with near-perfect correlation to human intestinal absorption.